A Phase 3 interventional study of Adalimumab and Placebo in Ulcerative Colitis (UC), sponsored by AbbVie. Completed at 173 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing adalimumab in Colitis, Ulcerative — 1 open to participants now, 2 under way, none of them phase 3. Adalimumab · Colitis, Ulcerative.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, this one has the largest enrollment, is one of 2 that started in 2014, is one of 10 in phase 3, and was the 10th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →1 of the 18 studies testing adalimumab in Colitis, Ulcerative is open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 952 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 152 across the 18 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 18 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
53 studies in Colitis, Ulcerative by AbbVie: 6 open now, 13 under way, 5 of them phase 3. Of 36 finished, 22 (61%) have results posted.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 6th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2014, is one of 19 in phase 3, and was the 15th registered.
AbbVie’s Colitis, Ulcerative studies by the year they started, since 2000.
1 of the studies testing adalimumab in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing adalimumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
Drug: Adalimumab · Other: Placebo
Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
Drug: Adalimumab
Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
Drug: Adalimumab · Other: Placebo
Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
Drug: Adalimumab
Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
Drug: Adalimumab · Other: Placebo
Also known as: Humira
Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Week 8
Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Time frame: Week 52
Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 8
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.
Time frame: Week 8
Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.
Time frame: Week 8
Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore \> 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopy subscore provided by the central reader.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic remission is defined as an endoscopy subscore of 0.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.
Time frame: Week 52
Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 \[severe problem\] to 7 \[normal health\]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.
Time frame: Week 52
This study included a Main Study (120 sites in 19 countries) and a Japan Sub-Study (22 sites in Japan). After a 3-week screening period, participants were randomized 3:2 to an 8-week double-blind (DB) Induction Period with 2 adalimumab dosing regimens (Induction Standard Dose \[I-SD\] or Induction Higher Dose \[I-HD\]).
| Milestone | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD | Maintenance (Main Study): TDM Regimen |
|---|---|---|---|---|---|
| Started | 379 | 573 | 0 | 0 | 0 |
| Enrolled in main study | 340 | 512 | 0 | 0 | 0 |
| Enrolled in japan sub-study | 39 | 61 | 0 | 0 | 0 |
| Completed | 332 | 514 | 0 | 0 | 0 |
| Not completed | 47 | 59 | 0 | 0 | 0 |
| Withdrew: Adverse event | 13 | 19 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 5 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 22 | 27 | 0 | 0 | 0 |
| Withdrew: Requires alternative/prohibited therapy | 4 | 5 | 0 | 0 | 0 |
| Withdrew: Subject noncompliance | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 3 | 2 | 0 | 0 | 0 |
| Milestone | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD | Maintenance (Main Study): TDM Regimen |
|---|---|---|---|---|---|
| Started | 0 | 0 | 345 | 350 | 151 |
| Completed | 0 | 0 | 221 | 246 | 105 |
| Not completed | 0 | 0 | 124 | 104 | 46 |
| Withdrew: Adverse event | 0 | 0 | 25 | 22 | 11 |
| Withdrew: Withdrawal by subject | 0 | 0 | 11 | 5 | 7 |
| Withdrew: Lost to follow-up | 0 | 0 | 4 | 1 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 70 | 55 | 19 |
| Withdrew: Requires alternative/prohibited therapy | 0 | 0 | 7 | 3 | 4 |
| Withdrew: Subject non-compliance | 0 | 0 | 1 | 3 | 2 |
| Withdrew: Other, not specified | 0 | 0 | 6 | 14 | 2 |
| Withdrew: Unknown reason | 0 | 0 | 0 | 1 | 0 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8 | 10.9 | 13.3 | 11.6 | 13.8 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per FMS) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease from baseline in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52 | 29.0 | 39.5 | 30.1 | 41.1 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 1: Percentage of Participants With Endoscopic Improvement at Week 8 | 27.1 | 31.1 | 26.9 | 30.5 |
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 2: Percentage of Participants With Fecal Calprotectin < 150 mg/kg at Week 8 | 27.1 | 31.1 | 26.9 | 30.5 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 3: Percentage of Participants With Inflammatory Bowel Disease Questionnaire (IBDQ) Response (Increase of IBDQ ≥ 16 From Baseline) at Week 8 | 60.9 | 67.2 | 60.7 | 65.3 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical response is defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 4: Percentage of Participants With Clinical Response Per FMS at Week 8 | 40.0 | 47.1 | 38.8 | 47.3 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Endoscopic remission is defined as an endoscopy subscore of 0.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 5: Percentage of Participants With Endoscopic Remission at Week 8 | 10.0 | 13.1 | 10.0 | 12.9 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The range for Bowel Symptom domain score is 10 (severe problem) to 70 (normal health). Response in IBDQ Bowel Symptom domain is defined as an increase of IBDQ Bowel Symptom domain score ≥ 6.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 6: Percentage of Participants Achieving Response in IBDQ Bowel Symptom Domain at Week 8 | 63.2 | 71.3 | 63.1 | 69.8 |
The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). The IBDQ Fatigue item score range is from 1 (severe problem) to 7 (normal health). Response is defined as an increase of IBDQ Fatigue item score ≥ 1.
| percentage of participants | Induction (Main Study): I-SD | Induction (Main Study): I-HD | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD |
|---|---|---|---|---|
| Induction Period Ranked Secondary Endpoint 7: Percentage of Participants Achieving Response in IBDQ Fatigue Item at Week 8 | 57.1 | 61.1 | 57.5 | 59.9 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 1: Percentage of Week 8 Responders (Per FMS) With Endoscopic Improvement at Week 52 | 41.4 | 51.3 | 41.7 | 52.0 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 2: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52 | 53.3 | 74.7 | 54.4 | 74.1 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders, per FMS, are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Clinical remission is defined as FMS ≤ 2 with no subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 3: Percentage of Week 8 Responders With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission at Week 52 | 27.2 | 38.9 | 28.2 | 39.8 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopy subscore provided by the central reader.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 4: Percentage of Week 8 Remitters (Per FMS) With Clinical Remission (Per FMS) at Week 52 | 40.5 | 57.1 | 44.4 | 55.8 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1. Endoscopy subscore provided by the central reader.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 5: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Improvement at Week 52 | 51.4 | 64.3 | 55.6 | 61.5 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 6: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days at Week 52 | 53.8 | 77.8 | 56.3 | 71.4 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 7: Percentage of Week 8 Remitters (Per FMS) With Steroid Usage at Baseline and Steroid Free at Least 90 Days and With Clinical Remission (Per FMS) at Week 52 | 34.6 | 55.6 | 37.5 | 51.4 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 8: Percentage of Week 8 Responders (Per FMS) With IBDQ Response (Increase of IBDQ ≥ 16 From Baseline) at Week 52 | 62.1 | 66.4 | 62.6 | 65.7 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-responders are defined as participants not meeting the criteria of response (defined as a decrease in FMS of ≥ 3 points and ≥ 30% from baseline, plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 9: Percentage of Week 8 Non-Responders With Clinical Remission (Per FMS) at Week 52 | 12.1 | 15.8 | 12.1 | 16.0 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 non-remitters are defined as participants not meeting the criteria of clinical remission at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 10: Percentage of Week 8 Non-Remitters With Clinical Remission (Per FMS) at Week 52 | 17.4 | 22.9 | 17.0 | 23.8 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders (per Full Mayo score) are defined as participants with a decrease in Full Mayo score of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. Endoscopic remission is defined as an endoscopy subscore of 0.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 11: Percentage of Week 8 Responders (Per FMS) With Endoscopic Subscore of 0 at Week 52 | 27.6 | 35.5 | 27.0 | 35.4 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 remitters are defined as participants with clinical remission (per FMS) at Week 8. Clinical remission is defined as a FMS ≤ 2 with no subscore \> 1. Endoscopic remission is defined as an endoscopy subscore of 0.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 12: Percentage of Week 8 Remitters (Per FMS) With Endoscopic Subscore of 0 at Week 52 | 45.9 | 47.6 | 42.2 | 44.2 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore \[RBS\] ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Bowel Symptom domain score range is 10 (severe problem) to 70 (normal health). Response is defined as increase of Bowel Symptom domain score ≥ 6 from baseline.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 13: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Bowel Symptom Domain at Week 52 | 62.1 | 69.7 | 62.6 | 71.4 |
The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The FMS ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Week 8 responders are defined as participants with a decrease in FMS of ≥ 3 points and ≥ 30% from Baseline plus a decrease in the rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1. The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Response in IBDQ fatigue item (range 1 \[severe problem\] to 7 \[normal health\]) is defined as increase of IBDQ fatigue item ≥ 1 from baseline.
| percentage of participants | Maintenance (Main Study): M-SD | Maintenance (Main Study): M-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD |
|---|---|---|---|---|
| Maintenance Period Ranked Secondary Endpoint 14: Percentage of Week 8 Responders (Per FMS) With Response in IBDQ Fatigue Item at Week 52 | 53.8 | 61.2 | 55.2 | 59.4 |
Collected over See time frame specifics detailed for each reporting group in their respective descriptions below. Participants were contacted 70 days following study drug discontinuation for an assessment of any new or ongoing adverse events, except those participants who continued on adalimumab therapy after the end of study participation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction (Main Study + Japan Sub-study): I-SD | 2/379 (0.5%) | 19/379 (5%) | 74/379 (19.5%) |
| Induction (Main Study + Japan Sub-study): I-HD | 4/573 (0.7%) | 22/573 (3.8%) | 112/573 (19.5%) |
| Maintenance (Main Study + Japan Sub-study): M-SD | 2/345 (0.6%) | 44/345 (12.8%) | 140/345 (40.6%) |
| Maintenance (Main Study + Japan Sub-study): M-HD | 2/350 (0.6%) | 44/350 (12.6%) | 141/350 (40.3%) |
| Maintenance (Main Study): TDM Regimen | 0/151 (0%) | 15/151 (9.9%) | 47/151 (31.1%) |
| Event | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD | Maintenance (Main Study): TDM Regimen |
|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 12/379 | 13/573 | 16/345 | 18/350 | 6/151 |
| PNEUMONIAInfections and infestations | 1/379 | 0/573 | 2/345 | 4/350 | 0/151 |
| CLOSTRIDIUM DIFFICILE INFECTIONInfections and infestations | 0/379 | 1/573 | 3/345 | 0/350 | 0/151 |
| ANAEMIABlood and lymphatic system disorders | 3/379 | 2/573 | 1/345 | 3/350 | 0/151 |
| MALLORY-WEISS SYNDROMEGastrointestinal disorders | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| UPPER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| BILE DUCT STONEHepatobiliary disorders | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| PORTOSPLENOMESENTERIC VENOUS THROMBOSISHepatobiliary disorders | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| BRONCHITISInfections and infestations | 0/379 | 0/573 | 0/345 | 0/350 | 1/151 |
| Event | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Maintenance (Main Study + Japan Sub-study): M-SD | Maintenance (Main Study + Japan Sub-study): M-HD | Maintenance (Main Study): TDM Regimen |
|---|---|---|---|---|---|
| COLITIS ULCERATIVEGastrointestinal disorders | 20/379 | 18/573 | 60/345 | 47/350 | 23/151 |
| NASOPHARYNGITISInfections and infestations | 16/379 | 29/573 | 47/345 | 46/350 | 11/151 |
| HEADACHENervous system disorders | 23/379 | 48/573 | 17/345 | 22/350 | 8/151 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 11/379 | 18/573 | 23/345 | 23/350 | 5/151 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/379 | 6/573 | 22/345 | 19/350 | 9/151 |
| RASHSkin and subcutaneous tissue disorders | 11/379 | 10/573 | 11/345 | 20/350 | 4/151 |
| Age, Continuous(years) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| Mean | 40.2 ± 13.14 | 40.5 ± 12.89 | 40.4 ± 12.98 |
| Sex: Female, Male(Participants) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| Female | 166 | 239 | 405 |
| Male | 213 | 334 | 547 |
| Race/Ethnicity, Customized(Participants) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| White | 326 | 484 | 810 |
| Black or African American | 8 | 16 | 24 |
| Asian | 44 | 70 | 114 |
| Native Hawaiian/Other Pacific Islander | 0 | 1 | 1 |
| Multiracial | 1 | 1 | 2 |
| Missing | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| Hispanic or Latino | 19 | 28 | 47 |
| Japanese | 39 | 61 | 100 |
| Other, Not Specified | 321 | 484 | 805 |
| Region(Participants) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| United States | 65 | 113 | 178 |
| Non-United States | 314 | 460 | 774 |
| Full Mayo Score (FMS)(units on a scale) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| Mean | 8.69 ± 1.509 | 8.87 ± 1.571 | 8.80 ± 1.548 |
| FMS: Rectal Bleeding Subscore(units on a scale) | Induction (Main Study + Japan Sub-study): I-SD | Induction (Main Study + Japan Sub-study): I-HD | Total |
|---|---|---|---|
| Mean | 1.68 ± 0.955 | 1.75 ± 0.967 | 1.72 ± 0.962 |
Showing the first 100 of 173 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Mar 2014 to primary completion in Sep 2019, 65 months.
Results were first posted in Oct 2020, 1 year 1 month after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 65 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab